Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759 · see citing works

Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group

Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543 · see citing works

Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients

Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435 · see citing works

Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma

Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366 · see citing works

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients

Haak, H. R., Hermans, J., van de Velde, C., Lentjes, E. G. W. M., Goslings, B. M., Fleuren, G. J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329 · see citing works

Adrenal cortical carcinoma

Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271 · see citing works

The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients

Crucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P. (1996) · Surgery · doi:10.1016/s0039-6060(96)80164-4 · Cited by 247 · see citing works

Prognostic parameters of metastatic adrenocortical carcinoma

Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236 · see citing works

CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD

Bergenstal, D. M., Hertz, R., Lipsett, M. B., & Moy, R. H. (1960) · Annals of Internal Medicine · doi:10.7326/0003-4819-53-4-672 · Cited by 230 · see citing works

Management of adrenocortical carcinoma

Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214 · see citing works

The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic simplications of serum level monitoring

van Slooten, H., Moolenaar, A. J., van Seter, A. P., & Smeenk, D. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90033-6 · Cited by 198 · see citing works

Mitotane Use in Inoperable Adrenal Cortical Carcinoma

Lubitz, J. A. (1973) · JAMA · doi:10.1001/jama.1973.03220100011003 · Cited by 186 · see citing works

Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery.

Icard, P., Chapuis, Y., Andréassian, B., Bernard, A., & Proye, C. A. G. (1992) · PubMed · Cited by 179 · see citing works

Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane

Grubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158 · see citing works

The Cleveland Clinic experience with adrenal cortical carcinoma

Bodie, B., Novick, A. C., Pontes, J. E., Straffon, R. A., Montie, J. E., Babiak, T., Sheeler, L., & Schumacher, P. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)40734-8 · Cited by 145 · see citing works

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma

Abraham, J., Bakke, S., Rutt, A., Meadows, B., Merino, M. J., Alexander, R. H., Schrump, D. S., Bartlett, D., Choyke, P. L., Robey, R. W., et al. (2002) · Cancer · doi:10.1002/cncr.10487 · Cited by 120 · see citing works

Analysis of prognosis and disease progression after local recurrence of melanoma

Dong, X. D., Tyler, D. S., Johnson, J. L., DeMatos, P., & Seigler, H. F. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5 · Cited by 111 · see citing works

Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel

Berruti, A., Faßnacht, M., Baudin, É., Hammer, G. D., Haak, H. R., Leboulleux, S., Skogseid, B. M., Allolio, B., & Terzolo, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5958 · Cited by 105 · see citing works

Mitotane Enhances Cytotoxicity of Chemotherapy in Cell Lines Expressing a Multidrug Resistance Gene (mdr-1/P-Glycoprotein) which is also Expressed by Adrenocortical Carcinomas

Bates, S. E., Shieh, C.-Y., Mickley, L. A., Dichek, H. L., Gazdar, A. F., Loriaux, D. L., & Fojo, A. T. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-1-18 · Cited by 94 · see citing works

BIOLOGICAL STUDIES ON AN ADRENOCORTICOLYTIC AGENT AND THE ISOLATION OF THE ACTIVE COMPONENTS123

Cueto, C., & BROWN, J. H. U. (1958) · Endocrinology · doi:10.1210/endo-62-3-334 · Cited by 92 · see citing works

The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane

Wängberg, B., Khorram‐Manesh, A., Jansson, S., Nilsson, B., Nilsson, O., Jakobsson, C. E., Lindstedt, S., Odén, A., & Ahlman, H. K. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0190 · Cited by 75 · see citing works

Adjuvant Mitotane for Adrenocortical Cancer—A Recurring Controversy

Huang, H., & Fojo, T. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0579 · Cited by 64 · see citing works

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma

Malandrino, P., Ghuzlan, A. A., Castaing, M., Young, J., Caillou, B., Travagli, J., Elias, D. M., de Baère, T., Dromain, C., Paci, A., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0341 · Cited by 60 · see citing works

Metabolic Activation and Binding of Mitotane in Adrenal Cortex Homogenates

Cai, W., Counsell, R. E., Djanegara, T., SCHTEINGART, D. E., Sinsheimer, J. E., & Wotring, L. L. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840203 · Cited by 56 · see citing works

Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria

Martz, F., & Straw, J. A. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00240-5 · Cited by 55 · see citing works

Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p′-DDD] and its p,p′- and m,p′-isomers

Cai, W., Benitez, R., Counsell, R. E., Djanegara, T., SCHTEINGART, D. E., Sinsheimer, J. E., & Wotring, L. L. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00028-x · Cited by 36 · see citing works

Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma

Baudin, É., Docao, C., Gicquel, C., Vassal, G., Bachelot, A., Penfornis, A., & Schlumberger, M. J. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf291 · Cited by 33 · see citing works

Systemic availability of o,p’-ddd in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism

Watson, A. D. J., Rijnberk, A., & Moolenaar, A. J. (1987) · Research in Veterinary Science · doi:10.1016/s0034-5288(18)30766-5 · Cited by 31 · see citing works

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works

Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.

Kasperlik-Zaluska, A. A., & Cichocki, A. S. (2005) · PubMed · Cited by 14 · see citing works

Adrenal cortical atrophy and liver damage produced in dogs by feeding 2,2-bis-(parachloro-phenyl)-1,1-dichloroethane.

Nelson, A. A., & Woodard, G. E. (1948) · PubMed · Cited by 12 · see citing works

Mitotane serum level analysis; good agreement between two different assays

Hermsen, I. G. C., den Hartigh, J., & Haak, H. R. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03787.x · Cited by 10 · see citing works

Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.

Seki, M., Nomura, K., Hirohara, D., Kanazawa, M., Sawada, T., Takasaki, K., & Demura, H. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060529 · Cited by 9 · see citing works

Untitled work

Venkatesh (1989) · doi:10.1002/1097-0142(19890801)64:3

Untitled work

Wooten (1993) · doi:10.1002/1097-0142(19931201)72:11

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976 · see citing works

Adrenocortical carcinoma

Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874 · see citing works

Update in Adrenocortical Carcinoma

Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414 · see citing works

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

Faßnacht, M., Berruti, A., Baudin, É., Demeure, M. J., Gilbert, J., Haak, H. R., Kroiß, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 342 · see citing works

Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Berruti, A., Baudin, É., Gelderblom, H. A. J., Haak, H. R., Porpiglia, F., Faßnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 330 · see citing works

Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics

Paci, A., Veal, G. J., Bardin, C., Levêque, D., Widmer, N., Beijnen, J. H., Astier, A., & Chatelut, É. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 261 · see citing works

Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment

Libé, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00045 · Cited by 233 · see citing works

Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells

Sbiera, S., Leich, E., Liebisch, G., Sbiera, I., Schirbel, A., Wiemer, L., Matysik, S., Eckhardt, C., Gardill, F., Gehl, A., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1367 · Cited by 194 · see citing works

Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial

Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175 · see citing works

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement

Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154 · see citing works

The role of surgery in the management of recurrent adrenocortical carcinoma

Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154 · see citing works

FATE1 antagonizes calcium‐ and drug‐induced apoptosis by uncoupling ER and mitochondria

Doghman, M., Granatiero, V., Sbiera, S., Sbiera, I., Lacas‐Gervais, S., Brau, F., Faßnacht, M., Rizzuto, R., & Lalli, E. (2016) · EMBO Reports · doi:10.15252/embr.201541504 · Cited by 144 · see citing works

Adrenocortical carcinoma — towards genomics guided clinical care

Crona, J., & Beuschlein, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0221-7 · Cited by 140 · see citing works

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma

Megerle, F., Herrmann, W., Schlötelburg, W., Ronchi, C. L., Pulzer, A., Quinkler, M. O., Beuschlein, F., Hahner, S., Kroiß, M., Faßnacht, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02591 · Cited by 135 · see citing works

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0242 · Cited by 134 · see citing works

Management of adrenal cancer: a 2013 update

Terzolo, M., Daffara, F., Ardito, A., Zaggia, B., Basile, V., Ferrari, L., & Berruti, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0049-2 · Cited by 108 · see citing works

Next-generation therapies for adrenocortical carcinoma

Altieri, B., Ronchi, C. L., Kroiß, M., & Faßnacht, M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101434 · Cited by 100 · see citing works

Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells

Hescot, S., Slama, A., Lombès, A., Paci, A., Remy, H., Leboulleux, S., Chadarévian, R., Trabado, S., Amazit, L., Young, J., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0368 · Cited by 98 · see citing works

Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma

Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Mueller, H. H., Skogseid, B. M., Leboulleux, S., Mantero, F., Haak, H. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2281 · Cited by 94 · see citing works

New perspectives for mitotane treatment of adrenocortical carcinoma

Puglisi, S., Calabrese, A., Basile, V., Pia, A., Reimondo, G., Perotti, P., & Terzolo, M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101415 · Cited by 91 · see citing works

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

Terzolo, M., Faßnacht, M., Perotti, P., Libé, R., Kaštelan, D., Lacroix, A., Arlt, W., Haak, H. R., Loli, P., Decoudier, B., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00193-6 · Cited by 90 · see citing works

THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome

Daniel, E., & Newell-Price, J. D. C. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1014 · Cited by 88 · see citing works

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art

Paragliola, R. M., Torino, F., Papi, G., Locantore, P., & Pontecorvi, A. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.62 · Cited by 85 · see citing works

Management of Adrenocortical Carcinoma

Jasim, S., & Habra, M. A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0773-7 · Cited by 82 · see citing works

Oncocytic Adrenocortical Tumors

Duregon, E., Volante, M., Cappia, S., Cuccurullo, A., Bisceglia, M., Wong, D., Spagnolo, D. V., Szpak‐Ulczok, S., Bollito, E., Daffara, F., et al. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822da401 · Cited by 70 · see citing works

Ribonucleotide Reductase Large Subunit ( <i>RRM1</i> ) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer

Volante, M., Terzolo, M., Fassnacht, M., Rapa, I., Germano, A., Sbiera, S., Daffara, F., Sperone, P., Scagliotti, G., Allolio, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2692 · Cited by 69 · see citing works

Adrenocortical carcinoma: The management of metastatic disease

Fay, A. P., Elfiky, A. A., Teló, G. H., McKay, R. R., Kaymakcalan, M. D., Nguyen, P. L., Vaidya, A., Ruan, D. T., Joaquim Bellmunt, B., & Choueiri, T. K. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.009 · Cited by 69 · see citing works

High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up

Mauclère-Denost, S., Leboulleux, S., Borget, I., Paci, A., Young, J., Ghuzlan, A. A., Deandreis, D., Drouard, L., Tabarin, A., Chanson, P., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0557 · Cited by 66 · see citing works

Adrenocortical Carcinoma

Baudin, É. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.03.001 · Cited by 66 · see citing works

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience

Laganà, M., Grisanti, S., Cosentini, D., Ferrari, V. D., Lazzari, B., Ambrosini, R., Sardini, C., Volta, A. D., Palumbo, C., Poliani, P. L., et al. (2020) · Cancers · doi:10.3390/cancers12040941 · Cited by 65 · see citing works

Pharmacological profile and effects of mitotane in adrenocortical carcinoma

Corso, C. R., Acco, A., Bach, C., Bonatto, S. J. R., de Figueiredo, B. C., & de Souza, L. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14721 · Cited by 67 · see citing works

Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Casa, S. D., Loli, P., Luconi, M., Mantero, F., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0349-9 · Cited by 61 · see citing works

Future directions in the diagnosis and medical treatment of adrenocortical carcinoma

Creemers, S. G., Hofland, L. J., Korpershoek, E., Franssen, G. J. H., van Kemenade, F. J., de Herder, W. W., & Feelders, R. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0452 · Cited by 59 · see citing works

The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells

Lehmann, T. P., Wrzesiński, T., & Jagodziński, P. P. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1244 · Cited by 58 · see citing works

Everolimus therapy for progressive adrenocortical cancer

Fraenkel, M., Gueorguiev, M., Barak, D. F., Salmon, A. Y., Grossman, A. B., & Gross, D. J. (2013) · Endocrine · doi:10.1007/s12020-013-9878-1 · Cited by 53 · see citing works

Surgical Resection of Synchronously Metastatic Adrenocortical Cancer

Dy, B. M., Strajina, V., Cayo, A. K., Richards, M. L., Farley, D. R., Grant, C. S., Harmsen, W. S., Evans, D. B., Grubbs, E. G., Bible, K. C., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3944-7 · Cited by 55 · see citing works

Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?

Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 51 · see citing works

Adrenocortical Carcinoma with Hypercortisolism

Puglisi, S., Perotti, P., Pia, A. R., Reimondo, G., & Terzolo, M. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.003 · Cited by 50 · see citing works

Adrenally Directed Medical Therapies for Cushing Syndrome

Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa778 · Cited by 51 · see citing works

Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy

Xu, Y., Zhu, Y., Shen, Z., Sheng, J.-Y., He, H., Ma, G., Qi, Y., Zhao, J., Wu, Y., Rui, W., et al. (2011) · Endocrine · doi:10.1007/s12020-011-9502-1 · Cited by 48 · see citing works

Immunotherapy failure in adrenocortical cancer: where next?

Cosentini, D., Grisanti, S., Volta, A. D., Laganà, M., Fiorentini, C., Perotti, P., Sigala, S., & Berruti, A. (2018) · Endocrine Connections · doi:10.1530/ec-18-0398 · Cited by 48 · see citing works

Recent advances in adrenocortical carcinoma in adults

Bourdeau, I., MacKenzie-Feder, J., & Lacroix, A. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283602274 · Cited by 47 · see citing works

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment

Puglisi, S., Calabrese, A., Basile, V., Ceccato, F., Scaroni, C. M., Simeoli, C., Torlontano, M., Cannavò, S., Arnaldi, G., Stigliano, A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111850 · Cited by 45 · see citing works

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer

Basile, V., Puglisi, S., Calabrese, A., Pia, A. R., Perotti, P., Berruti, A., Reimondo, G., & Terzolo, M. (2020) · Cancers · doi:10.3390/cancers12092615 · Cited by 44 · see citing works

Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?

Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 42 · see citing works

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens

Tran, T. B., Wang, J., Doi, Y., Velkov, T., Bergen, P. J., & Li, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00721 · Cited by 44 · see citing works

Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane

D’Avolio, A., Francia, S. D., Basile, V., Cusato, J., Martino, F., Pirro, E., Piccione, F. M., Ardito, A., Zaggia, B., Volante, M., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283606cb2 · Cited by 42 · see citing works

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma

Puglisi, S., Calabrese, A., Basile, V., Ceccato, F., Scaroni, C. M., Altieri, B., Casa, S. D., Loli, P., Pivonello, R., Martino, M. C. D., et al. (2020) · Cancers · doi:10.3390/cancers12030740 · Cited by 41 · see citing works

Practical treatment using mitotane for adrenocortical carcinoma

Terzolo, M., Zaggia, B., Allasino, B., & Francia, S. D. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000056 · Cited by 40 · see citing works

Effects of mitotane on the hypothalamic–pituitary–adrenal axis in patients with adrenocortical carcinoma

Reimondo, G., Puglisi, S., Zaggia, B., Basile, V., Saba, L., Perotti, P., Francia, S. D., Volante, M., Zatelli, M. C., Cannavò, S., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0452 · Cited by 36 · see citing works

The molecular basis of adrenocortical cancer

Lehmann, T. P., & Wrzesiński, T. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.02.009 · Cited by 34 · see citing works

Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells

Lin, C.-W., Chang, Y., & Pu, H. (2012) · Toxicology · doi:10.1016/j.tox.2012.04.007 · Cited by 34 · see citing works

Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study

Altieri, B., Sbiera, S., Herterich, S., Francia, S. D., Casa, S. D., Calabrese, A., Pontecorvi, A., Quinkler, M. O., Kienitz, T., Mannelli, M., et al. (2020) · Cancers · doi:10.3390/cancers12020359 · Cited by 34 · see citing works

Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma

Hescot, S., Seck, A., Guérin, M., Cockenpot, F., Huby, T., Broutin, S., Young, J., Paci, A., Baudin, É., & Lombès, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2080 · Cited by 34 · see citing works

Management of adjuvant mitotane therapy following resection of adrenal cancer

Terzolo, M., Ardito, A., Zaggia, B., Laino, F., Germano, A., Francia, S. D., Daffara, F., & Berruti, A. (2012) · Endocrine · doi:10.1007/s12020-012-9719-7 · Cited by 33 · see citing works

Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro

Theile, D., Haefeli, W. E., & Weiß, J. (2014) · Endocrine · doi:10.1007/s12020-014-0517-2 · Cited by 33 · see citing works

Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

Claps, M., Cerri, S., Grisanti, S., Lazzari, B., Ferrari, V. D., Roca, E., Perotti, P., Terzolo, M., Sigala, S., & Berruti, A. (2017) · Endocrine · doi:10.1007/s12020-017-1428-9 · Cited by 31 · see citing works

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies

Iacono, M. L., Puglisi, S., Perotti, P., Saba, L., Petiti, J., Giachino, C., Reimondo, G., & Terzolo, M. (2021) · Cancers · doi:10.3390/cancers13215255 · Cited by 30 · see citing works

Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study

Weigand, I., Altieri, B., Lacombe, A. M. F., Basile, V., Kircher, S., Landwehr, L., Schreiner, J., Zerbini, M. C. N., Ronchi, C. L., Megerle, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa293 · Cited by 31 · see citing works

The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition

Scheidt, H. A., Haralampiev, I., Theisgen, S., Schirbel, A., Sbiera, S., Huster, D., Kroiß, M., & Müller, P. K. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.022 · Cited by 28 · see citing works

ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma

Terzolo, M., & Faßnacht, M. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0260 · Cited by 30 · see citing works

Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function

Gentilin, E., Tagliati, F., Terzolo, M., Zoli, M., Lapparelli, M., Minoia, M., Ambrosio, M. R., Uberti, E. C. D., & Zatelli, M. C. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0210 · Cited by 27 · see citing works

RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization

Germano, A., Rapa, I., Volante, M., Francia, S. D., Migliore, C., Berruti, A., Papotti, M. G., & Terzolo, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.11.027 · Cited by 25 · see citing works

Medical Therapy for Cushing’s Syndrome in the Twenty-first Century

Tritos, N. A., & Biller, B. M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.006 · Cited by 24 · see citing works

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging

Haider, M. S., Ahmad, T., Gröll, J., Scherf‐Clavel, O., Kroiß, M., & Luxenhofer, R. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00700-5 · Cited by 26 · see citing works

The Lack of Antitumor Effects of o,p′DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment

Hescot, S., Paci, A., Seck, A., Slama, A., Viengchareun, S., Trabado, S., Brailly‐Tabard, S., Ghuzlan, A. A., Young, J., Baudin, É., et al. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0189-7 · Cited by 24 · see citing works

Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study

Tran, T. B., Bergen, P. J., Creek, D. J., Velkov, T., & Li, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00359 · Cited by 23 · see citing works

Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry

Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Hescot, S., Körbl, D., Megerle, F., Beuschlein, F., Neu, B., Quinkler, M. O., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0747-5571 · Cited by 23 · see citing works

Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study

Berruti, A., Libé, R., Laganà, M., Ettaieb, H., Sukkari, M. A., Bertherat, J. Y., Feelders, R. A., Grisanti, S., Cartry, J., Mazziotti, G., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0026 · Cited by 23 · see citing works

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?

Cazaubon, Y., Talineau, Y., Féliu, C., Konecki, C., Russello, J., Mathieu, O., & Djerada, Z. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110566 · Cited by 23 · see citing works

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma

Poirier, J., Gagnon, N., Terzolo, M., Puglisi, S., Ghorayeb, N. E., Calabrese, A., Lacroix, A., & Bourdeau, I. (2020) · Cancers · doi:10.3390/cancers12030639 · Cited by 23 · see citing works

Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma

Kroiß, M., Plonné, D., Kendl, S., Schirmer, D., Ronchi, C. L., Schirbel, A., Zink, M., Lapa, C., Klinker, H., Faßnacht, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0946 · Cited by 23 · see citing works

Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors

For Comete-Cancer Network, Vezzosi, D., Cao, C. D., Hescot, S., Bertherat, J. Y., Haissaguerre, M., Bongard, V., Drui, D., de la Fouchardière, C., Illouz, F., et al. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0313-6 · Cited by 23 · see citing works

Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide

on behalf of the German Adrenocortical Carcinoma Study Group, Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Neu, B., Müller, H., Quinkler, M. O., Hahner, S., Heidemeier, A., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0260-7 · Cited by 22 · see citing works

microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma

Kwok, G., Zhao, J., Glover, A. R., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Ip, J. C. Y., & Sidhu, S. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0849 · Cited by 22 · see citing works

A Micellar Mitotane Formulation with High Drug‐Loading and Solubility: Physico‐Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models

Haider, M. S., Schreiner, J., Kendl, S., Kroiß, M., & Luxenhofer, R. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900178 · Cited by 21 · see citing works

Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19 · see citing works

The challenge of developmental therapeutics for adrenocortical carcinoma

da Costa, R. B., Carneiro, B. A., Tavora, F., Pai, S. G., Kaplan, J. B., Chae, Y. K., Chandra, S., Kopp, P. A., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8774 · Cited by 21 · see citing works

Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?

Gontijo, A. V. L., Pereira, S. L., & Bonfante, H. D. L. (2021) · Current Microbiology · doi:10.1007/s00284-021-02693-5 · Cited by 24 · see citing works

Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?

Cremaschi, V., Abate, A., Cosentini, D., Grisanti, S., Rossini, E., Laganà, M., Tamburello, M., Turla, A., Sigala, S., & Berruti, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2106128 · Cited by 21 · see citing works

Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients

Maiter, D. M., Bex, M., Vroonen, L., T'Sjoen, G. G., Gil, T., Banh, C., & Chadarévian, R. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.02.005 · Cited by 20 · see citing works

Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters

Payabyab, E. C., Balasubramaniam, S., Edgerly, M., Velarde, M., Merino, M. J., Venkatesan, A. M., Leuva, H., Litman, T., Bates, S. E., & Fojo, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1570 · Cited by 20 · see citing works

New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma

Stigliano, A., Cerquetti, L., Lardo, P., Petrangeli, E., & Toscano, V. (2017) · Oncology Reports · doi:10.3892/or.2017.5427 · Cited by 20 · see citing works

ENSAT registry-based randomized clinical trials for adrenocortical carcinoma

Crona, J., Baudin, É., Terzolo, M., Chrisoulidou, A., Angelousi, A. G., Ronchi, C. L., Lamas, C., van Dijkum, E. J. M. N., Ceccato, F., Borson‐Chazot, F., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0800 · Cited by 20 · see citing works

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane

van Koetsveld, P. M., Vitale, G., Feelders, R. A., Waaijers, M., Sprij-Mooij, D. M., de Krijger, R. R., Speel, E. M., Hofland, J., Lamberts, S. W. J., de Herder, W. W., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0217 · Cited by 20 · see citing works

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells

Kroiß, M., Sbiera, S., Kendl, S., Kurlbaum, M., & Faßnacht, M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0273-2 · Cited by 19 · see citing works

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy

Ghorayeb, N. E., Rondeau, G., Latour, M., Cohade, C., Olney, H. J., Lacroix, A., Perrotte, P., Sabourin, A., Mazzuco, T. L., & Bourdeau, I. (2016) · Medicine · doi:10.1097/md.0000000000003180 · Cited by 20 · see citing works

A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring

Friedl, B., Kurlbaum, M., Kroiß, M., Faßnacht, M., & Scherf‐Clavel, O. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01868-1 · Cited by 19 · see citing works

Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC

Warde, K. M., Schoenmakers, E., Martínez, E. R., Lim, Y. J., Leonard, M., Lawless, S. J., O’Shea, P. M., Chatterjee, K., Gurnell, M., Hantel, C., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0031 · Cited by 18 · see citing works

Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients

Arshad, U., Taubert, M., Kurlbaum, M., Frechen, S., Herterich, S., Megerle, F., Hamacher, S., Faßnacht, M., Fuhr, U., & Kroiß, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0342 · Cited by 19 · see citing works

Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth

Trotta, F., Avena, P., Chimento, A., Rago, V., Luca, A. D., Sculco, S., Nocito, M. C., Malivindi, R., Fallo, F., Pezzani, R., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1063 · Cited by 18 · see citing works

Xenograft models for preclinical drug testing: Implications for adrenocortical cancer

Luconi, M., & Mannelli, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.043 · Cited by 17 · see citing works

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells

Germano, A., Saba, L., Francia, S. D., Rapa, I., Perotti, P., Berruti, A., Volante, M., & Terzolo, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196931 · Cited by 16 · see citing works

Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures

Grisanti, S., Cosentini, D., Laganà, M., Abate, A., Rossini, E., Sigala, S., & Berruti, A. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.07.007 · Cited by 15 · see citing works

The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients

Calabrese, A., Puglisi, S., Borin, C., Basile, V., Perotti, P., Pia, A. R., Berchialla, P., Volante, M., Fiori, C., Porpiglia, F., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad002 · Cited by 15 · see citing works

Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma.

Ferrero, A., Sperone, P., Ardito, A., Rossi, G., Buono, S. D., Priola, A. M., Sergio Bracarda, A., Taberna, E., Terzolo, M., & Berruti, A. (2013) · PubMed · doi:10.3275/8334 · Cited by 15 · see citing works

Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells

Bikas, A., Jensen, K. E., Patel, A. D., Costello, J. M., Kaltsas, G., Hoperia, V., Wartofsky, L., Burman, K. D., & Vasko, V. V. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4802 · Cited by 15 · see citing works

Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience

Uchihara, M., Tanioka, M., Kojima, Y., Nishikawa, T., Sudo, K., Shimoi, T., Noguchi, E., Maeshima, A. M., & Yonemori, K. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02021-8 · Cited by 14 · see citing works

A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma

Flauto, F., Martino, M. C. D., Vitiello, C., Pivonello, R., Colao, A., & Damiano, V. (2024) · Cancers · doi:10.3390/cancers16234061 · Cited by 12 · see citing works

Abstract 1671: A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients

Garg, M. B., Sakoff, J. A., & Ackland, S. P. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-1671 · Cited by 1 · see citing works

Plasma Concentration of o,p'DDD (Mitotane), o,p'DDA and o,p'DDE as Predictors of Tumor Response in Adrenocortical Carcinoma: Results of a Retrospective European Network for the Study of Adrenal Tumors (ENS@T) Multicentre Study.

Hermsen, I. G. C., Faßnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Allolio, B., Berruti, A., Chadarévian, R., et al. (2010) · The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego · doi:10.1210/endo-meetings.2010.part3.p2.p3-77

Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.

Kasperlik-Zaluska, A. A., & Cichocki, A. S. (2005) · PubMed · Cited by 14 · see citing works

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0242 · Cited by 134 · see citing works